MannKind Provides Business Updates and 2026 Growth Drivers

About this update from Mannkind Corporation

[{"type":"image","alt":"MannKind","displaySize":"","headline":null,"caption":"MannKind","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":157,"url":"https://media.zenfs.com/en/globenewswire.com/25877a202ba02abe901e1a60c89ab7e1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Hy4_XAO3Mr5IV48Ac_Z8Gw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/25877a202ba02abe901e1a60c89ab7e1","width":300,"height":157}},"lazy":false},{"type":"text","content":"DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today provided business updates and outlined anticipated growth drivers for 2026, including progress across its commercial programs and clinical development initiatives.","length":452,"tagName":"p"},{"type":"text","content":"“MannKind closed 2025 on a high note, marked by milestones that reinforce our growth trajectory—including the acquisition of scPharmaceuticals and a record-setting fourth quarter surpassing $100 million in net revenue,” said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation. “With two high-potential launches on the horizon, 2026 is shaping up to be a catalyst-rich year that positions MannKind for long-term value creation.”","length":450,"tagName":"p"},{"type":"text","content":"Major Catalysts Driving 2026: ","length":29,"tagName":"p"},{"type":"text","content":"Afrezza® (insulin human) Inhalation Powder","length":42,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"FDA decision on Afrezza label update (dose conversion) anticipated with a PDUFA target action date of January 23, 2026","length":118,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Would update the initial dose for mealtime insulin when switching from subcutaneous rapid-acting insulin","length":104,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":104,"olType":false}]},{"val":[{"type":"text","content":"FDA accepted for review the supplemental Biologics License Application (sBLA) for Afrezza® Inhalation Powder in children and adolescents living with type 1 or type 2 diabetes with a PDUFA tar...

More updates from Mannkind Corporation